within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA22_Cloxazolam;

model Cloxazolam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 5e-07,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0011666666666666668,
    Tlag = 600,
    Vdp = 0.0007,
    k12 = 1.6666666666666668e-07,
    k21 = 1.6666666666666668e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cloxazolam</td></tr><tr><td>ATC code:</td><td>N05BA22</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>30</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cloxazolam is a benzodiazepine derivative used as an anxiolytic and for the treatment of anxiety disorders. It has sedative and muscle-relaxant properties. The drug is no longer widely used in most countries and is not currently FDA-approved in the United States, but is still marketed in Japan and a few other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on class similarity to other oral benzodiazepines (e.g., diazepam) given the absence of direct published PK studies for cloxazolam in the literature. Assumed for a typical healthy adult population, single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05BA22 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cloxazolam;
